Patent ID: 11931412
Assignee: WASHINGTON UNIVERSITY
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 18:
19. The method of claim 1, wherein the JAK1 inhibitor is selected from one or more of the group consisting of: tofacitinib, ruxolitinib, baricitinib, itacitnib (INCB039110), oclacitinib, AZD1480, fedratinib, AT9283, AG-490, momelotinib, TG101209, gandotinib, NVP-BSK805, AZ 960, CEP-33779, Pacritinib, XL019, S-Ruxolitinib, ZM 39923, Decernotinib, Cerdulatinib, filgotinib, FLLL32, BMS-911543, peficitinib, GLPG0634, GLPG0634 analogue, Go6976, curcumol, cucurbitacin, lestaurtinib, upadacitinib, CHZ868, Solcitinib (GSK 2586184), NS-018; or a pharmaceutically acceptable salt thereof.